USA Quality Factor Ishares Edge MSCI ETF (QUAL)
$102.88 0.97 (0.93%)
20:00 EDT QUAL Stock Quote Delayed 30 Minutes
Previous Close $102.88
Market Cap 5.31B
PE Ratio -
Volume (Avg. Vol.) 717,700
Day's Range 102.16 - 104.32
52-Week Range 68.20 - 110.42
Dividend & Yield 1.50 (1.46%)
QUAL Stock Predictions, Articles, and USA Quality Factor Ishares Edge MSCI ETF News
- From InvestorPlace
- From the Web
The other prominent theme has been investors' ongoing affinity for inexpensive ETFs. While not all of the best ETFs are extremely cheap, there are plenty of strong funds out there with low expense ratios and those fees are falling. Additionally, basically every brokerage firm of note eliminated commissions on ETFs this year, so the asset class is becoming even more cost-effective to embrace.
Quality ETFs can have different definitions, but these are all ETFs to buy for stability and long-term gains.
If you think the bull market will continue you, these 7 ETFs are set up to profit from the markets' move up.
Most smart-beta ETFs are falling flat on their promises. But these three are as good as gold and actually deliver the goods.
It doesn't matter if stocks are overvalued as long as there's a more foolish player willing to pay a higher price. Don't let that person be you
Many of the best index funds for defending against a few months of volatility are also among the best funds to simply hold for the long-term.
Liz Ann Sonders, chief investment strategist at Charles Schwab, commented that retail investors are not adding to stock holdings. Buybacks are holding up the market
Debt and interest levels continue to rise across the corporate board. This puts earnings at risk, which should concern investors for the future.
The biggest abusers of debt today are corporations. The fallout is coming, particularly when it comes to some of the unwise stock buybacks programs in place
The most common definition of a bear market is a fall of 20% from a high-water mark. US markets are not there yet, but warning signs are out
Some are interpreting recent bounces off S&P 500 lows as a sign that all's right with stocks again. Here's where are model portfolio stands on the news
Bull markets have corrections, and bear markets have rallies. Here is how we'll allocate our holdings into the next, inevitable, bear rally
Are corporations in great shape? Three consecutive quarters of declines in earnings and record high leverage suggest not. Here's our strategy
The strategy of banking gains on highly appreciated positions without considering these variables is a mistake too many investors make today
Jounce Therapeutics rallies on license deal with Gilead, Tracon Pharma follows, I-Mab, Kindred Biosciences among major losers
From Seeking Alpha
Gainers: Jounce Therapeutics (NASDAQ:JNCE) +42%, TRACON Pharmaceuticals (NASDAQ:TCON) +13.8%, Nano-X Imaging (NASDAQ:NNOX) +13.6%, Athenex (NASDAQ:ATNX) +11.5%, Surface Oncology (NASDAQ:SURF) +8%.Losers: I-Mab (NASDAQ:IMAB) -14.5%, Kindred Biosciences (NASDAQ:KIN) -13.7%, ProQR Therapeutics (NASDAQ:PRQR) -13%, Vaxart (NASDAQ:VXRT) -12.9%, ADiTx Therapeutics (NASDAQ:ADTX) -12.2%.